Similar articles

• [Field trial of influenza virus hemagglutinin vaccine (author's transl)].

  Kimura Y. Kimura Y. Fukuoka Igaku Zasshi. 1975 May;66(5):321-42. Fukuoka Igaku Zasshi. 1975. PMID: 1236825 Japanese. No abstract available.
• Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

  Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Hehme N, et al. Virus Res. 2004 Jul;103(1-2):163-71. doi: 10.1016/j.virusres.2004.02.029. Virus Res. 2004. PMID: 15163505 Clinical Trial.
• Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.

  Robuccio JA, Griffith JW, Chroscinski EA, Cross PJ, Light TE, Lang CM. Robuccio JA, et al. Lab Anim Sci. 1995 Aug;45(4):420-6. Lab Anim Sci. 1995. PMID: 7474883
• MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

  O'Hagan DT. O'Hagan DT. Expert Rev Vaccines. 2007 Oct;6(5):699-710. doi: 10.1586/14760584.6.5.699. Expert Rev Vaccines. 2007. PMID: 17931151 Review.
• Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.

  Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Moser C, et al. Expert Rev Vaccines. 2007 Oct;6(5):711-21. doi: 10.1586/14760584.6.5.711. Expert Rev Vaccines. 2007. PMID: 17931152 Review.